Apogee Therapeutics, Inc.
APGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $2,500 | $1,415 | $1,076 |
| - Cash | $142 | $118 | $152 |
| + Debt | $12 | $2 | $0 |
| Enterprise Value | $2,370 | $1,299 | $924 |
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| EBITDA | -$217 | -$75 | -$40 |
| % Margin | – | – | – |
| Net Income | -$182 | -$84 | -$40 |
| % Margin | – | – | – |
| EPS Diluted | -3.3 | -1.66 | -0.79 |
| % Growth | -98.8% | -110.1% | – |
| Operating Cash Flow | -$171 | -$75 | -$16 |
| Capital Expenditures | -$1 | -$0 | $0 |
| Free Cash Flow | -$172 | -$75 | -$16 |